Navigating a Key Inflection Point in Biosimilar Sector M&A

The convergence of regulatory reform, a more navigable patent framework and a looming patent expiration cliff have transformed biosimilars from a slow-moving, high-friction business into one of the most active arenas for life sciences dealmaking. Skadden attorneys Rachel Turow, Samuel Cammer and Leslie Demers discuss some of the factors that are influencing the surge in M&A, including FDA reforms, a settlement-friendly patent litigation environment and the historic patent cliff.